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Abstract
Huntington’s disease (HD) cellular pathology is characterised by the aggregation of mutant
huntingtin (mHTT) protein into inclusion bodies. The present paper compared the sensitivity
of five widely used mHTT antibodies (S830; MW8; EM48; 1C2; ubiquitin) against mice from
five commonly used HDmouse models (R6/1; YAC128; HdhQ92; B6 HdhQ150; B6 x129/
Ola HdhQ150) at two ages to determine: the most sensitive antibodies for each model;
whether mHTT antibody binding differed depending on aggregation stage (diffuse versus
frank inclusion); the role of ubiquitin during aggregation as the ubiquitin proteosome system
has been implicated in disease development. The models demonstrated unique profiles of
antibody binding even when the models varied only by background strain (HdhQ150). MW8
was highly sensitive for detecting frank inclusions in all lines whereas EM48, ubiquitin and
1C2 demonstrated consistent staining in all models irrespective of age or form of mHTT.
MW8 and S830 were the most sensitive antibodies with 1C2 the least. Ubiquitin levels were
stable for each model regardless of age. Ubiquitin was particularly sensitive in young
YAC128 mice that demonstrate an absence of inclusions until ~12 months of age suggest-
ing high affinity to mHTT in its diffuse form. The data indicate that generalisations across
models regarding the quantification of aggregations may not be valid and that mHTT anti-
body binding is unique to the mouse model and sensitive to changes in inclusion
development.
Introduction
Huntington's disease (HD) is an inherited progressive neurodegenerative disorder caused by a
CAG repeat expansion in the first exon of HTT. HTT encodes the huntingtin protein (HTT)
and the CAG repeat tract gives rise to a polyglutamine tract in the protein [1]. The onset of the
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disease is generally in mid-life with death occurring 15–20 years later. HD is characterized by
characteristic motor and cognitive impairments and variable psychiatric symptoms, associated
with selective cellular dysfunction and neuronal loss first within the caudate nucleus and later
across the whole brain [2]. Neuronal intra-nuclear inclusions (NIIs) containing mutant HTT
(mHTT) have been reported in patients [3–8] and model systems that carry aHTT polygluta-
mine mutation [9–17]. The precise role that the aggregation process and HTT-positive inclu-
sions play in HD neuropathology remains unclear [6, 12, 18–29], but their presence in either
the early aggregation diffuse state or as frank NIIs are predictors of cell death [22, 28, 30] and
are at the very least, markers of regional neuropathology.
There are several mHTT antibodies that immunolabel mHTT. Within HD mouse models
the antibodies bind to different regions of the mHTT protein. Some have affinity specifically
for the expanded polyglutamine [31, 32] whilst others bind to the N—or C -terminal of the
exon 1 region [6, 33, 34]. The epitope specificity of the antibodies can characterise the inclu-
sions by showing the availability of different epitopes and therefore the potential conforma-
tional changes that mHTT undergoes during the development of inclusion formations [35].
The ubiquitin antibody has also been used to detect mHTT as it is sequestered during the
aggregation process.
The ubiquitin tagging of proteins, including those that are misfolded, marks them for degra-
dation via the ubiquitin-proteasome system (UPS) [36, 37]. Altered ubiquitination has been
proposed as a pathological mechanism in HD cell death [38–40] and inhibition of the protea-
some in HD cell produced an increases in mHTT aggregation [38, 41]. A recent study [26] sug-
gested that ubiquitination of NIIs is a late stage event in the development of the inclusion and
therefore of little pathological relevance, in contrast to an earlier report that ubiquitin staining
was already present in NIIs from their inception/early stages of formation [42]. Both of these
studies were limited by their use of a single antibody and a single HD mouse line (R6/2) mak-
ing an objective interpretation of ubiquitin binding within and beyond this single mouse line
difficult. Another recent study [43] found ubiquitin activity that increased with age in both cor-
tex and striatum of the 84Q transgenic HD mouse line, and although the authors claim the
increases appear prior to the onset of HD in the mice, the ubiquitin increase was consistent
with the appearance and progression of EM48 mHTT staining, suggestive of close and ongoing
interactions between the aggregation and ubiquitination processes. At present it is not clear
how ubiquitin interacts with mHTT and whether this is an early or late stage event in the devel-
opment of mHTT inclusion pathology.
As part of a larger programme of work characterising HD mouse lines, we sought to charac-
terise the ability of the most commonly used antibodies for the detection of mHTT (S830,
MW8, EM48, 1C2) within striatal tissue of 4 congenic (C57BL6/j hereafter referred to as B6)
HD mouse lines (R6/1, HdhQ92, YAC128, HdhQ150). Since there is a general movement to
breed genetically modified mouse lines to common background strains to overcome back-
ground strain confounds particularly in behavioural phenotypes, we included a second variant
of the HdhQ150 mouse line which was maintained on its original background strain (129/Ola
X C57BL/6 background) to determine the impact of background on aggregation neuropathol-
ogy. Our previous studies [44–47] demonstrated the predominance of early disease diffuse
mHTT staining to the staining of frank NIIs with age in these mouse lines, and thereby pro-
vided age groups for the present study for the comparison of antibody sensitivity to the differ-
ent forms of mHTT. We also sought to determine whether ubiquitin tagging of the mHTT in
HDmouse models is primarily related to mHTT in its diffuse state or associated in the devel-
opment of frank inclusion pathology as both notions have been suggested to be of importance
to the development of HD neuropathology [26, 42].
Assessment of mHTT Antibodies across HDMouse Lines
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Materials and Methods
Animals
All experiments were conducted under UK licence and in accordance with the UK Animals
(Scientific Procedures) Act 1986 and Cardiff Biological Standards Committee. All mice were
killed by lethal IP injection of Ethatal conforming to UK and European legislation.
The mice used were congenic to the C57BL/6 background with the exception of the
HdhQ150 mouse on the original 129/Ola X C57BL/6 background (see Table 1). For each line,
tissue samples were taken from 5–8 mutant gene carriers at 8 and 18 months of age to provide
“young” and “old” data points for each of the lines with the exception of the R6/1 mice that
have a shortened life span where tissue was taken at 4 and 7 months of age as being a propor-
tional life span representation of the other lines.
The R6/1 mice [15] were originally obtained from Jackson Laboratory (Maine, USA) and
backcrossed to the pure B6 background for>10 generations. The YAC128 mice [11] were
kindly supplied by the Hayden laboratory (University of British Columbia, Vancouver, Can-
ada) and were backcrossed on to a B6 background for>10 generations. The HdhQ92 mice
[48] were bred in-house but originated from stock animals (Jackson Laboratories, Maine,
USA), and backcrossed onto the B6 background over a minimum of six generations. The “orig-
inal”HdhQ150 mouse line[17] was bred in-house on the original mixed 129/Ola X B6 back-
ground strain and maintained on an F1 cross with a second line bred and maintained in house
on a pure B6 background.
All mice were genotyped commercially (Laragen Inc., Culver City, USA) by the tail tip sam-
ples as previously described [44–47]. Prior to sacrifice the mice were housed in mixed genotype
single-sex cages under standard animal laboratory conditions. Animals were kept on a 12 hour
lights on/off light-dark cycle (lights on 07:00h) with ad libitum access to food and water and an
ambient room temperature of 21±1°C.
Histology
Tissue preparation. All mice and tissues were treated in the same way throughout the tis-
sue handling process except where described. The mice were anaesthetized by intraperitoneal
injection of 0.2 ml of Euthetal (Merial, Essex, UK) and then perfused intracardially with phos-
phate-buffered saline (PBS, pH 7.4) for 3 min. Followed by 4% paraformaldehyde (PFA)
(Fisher Scientific, Loughborough, UK) in a 0.1M PBS solution, pH 7.4, for a further 5 min. The
Table 1. Characteristics of the mouse lines used in the present study.
Line CAG number
(mean)
Construct
R6/1 (B6) 124 Human exon 1 (15)
HdhQ92 (B6) 90 Hdh/HD exon 1 with human polyglutamine and ﬂanking
domains Htt (48)
YAC128 (B6) 126 Full Human HTT in genomic context (11)
HdhQ150 (B6) 146 Mouse Htt with human polyglutamine length (17)
HdhQ150 (B6 X
129Ola)
151 Mouse Htt with human polyglutamine length (17)
All but one of the mouse lines was bred on a C57BL6/j (shortened to B6) background and all varied by
CAG repeat length. The inserted genetic construct was of either a fragment (R6/1), artiﬁcial chromosome
(YAC128), or knock-in (HdhQ92 and HdhQ150).
doi:10.1371/journal.pone.0155834.t001
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brains were carefully removed, post fixed in 4% PFA for 4 h, and then transferred to 25%
sucrose in PBS for 24 h or until they sunk to the bottom of the container. The coronal sections
(40 μm) of the brain were cut in series of 1:12 using a freezing sledge microtome (Leitz Bright
Series 8000, Germany) and were cryoprotected by immersion in antifreeze solution. Prior to
immunohistochemistry tissue sections for each antibody were placed in (pH 7.4) TRIS Buffered
Saline (TBS), and washed twice for 5 min. Sections for the ubiquitin, S830, EM48 and MW8
antibodies were pre-treated with an antigen retrieval method by incubation in citrate buffer
(pH 6) for 20 min at 95C and for the 1C2 antibody which was insensitive to citric acid treat-
ment, a 90% formic acid solution was used for 5 min at room temperature. Methods were
adapted from in house-procedures and those previously described [10, 49]. Staining with all of
the primary antibodies was optimised based on previous reports prior to the study to determine
the optimal parameters for visualisation of mHTT staining.
mHTT Primary antibody immunohistochemistry. Endogenous peroxidise activity was
inhibited by incubation in methanol containing 3% H2O2 (VWR International, UK) for 5 min.
Non-specific binding sites were blocked with 3% horse serum in TBS for 1 h, and the sections
were incubated with ubiquitin (1:1000:1μl in 1ml TXTBS containing 1% horse serum), S830
(1:20000: 1μl in 20ml TXTBS containing 1% horse serum), EM48 (1:500: 0.5μl in 1ml TXTBS
containing 1% horse serum), MW8 (1:1000: 1μl in 1ml TXTBS containing 1% horse serum), or
1C2 (1:4000: 0.25μl in 1ml TXTBS containing 1% horse serum) antibodies overnight (~16
hours) at room temperature (21°± 2°C). After several washes in TBS, the sections were incu-
bated with a horse anti-goat secondary antibody for S830 or horse anti-mouse secondary anti-
body (diluted 1:200, Vector Laboratories, Burlingame, CA, USA) for MW8, EM48, ubiquitin
and 1C2 for 2 h at 21° ± 2°C. After several washes in TBS, the sections were incubated with a
biotin-streptavidin kit according to the manufacturer’s instructions (Vector Laboratories).
After which, the sections were rinsed in TBS. For each antibody the peroxidase activity was
visualized with 3,3’-diaminobenzidine (DAB: Sigma-Aldrich, Poole, UK), and the sections
mounted on gelatine-coated slides, prior to dehydration and cover-slipping (see Table 2 for
details).
It should be noted that the presence of the ubiquitin polypeptide is assessed but we present
no evidence that its presence is due to sequestration into the mHTT aggregate although this is
widely accepted (see above). Consequently, ubiquitin staining is described as diffuse or concen-
trated as an indicator that it may be associated with diffuse or aggregated mHTT staining
respectively.
Table 2. Summary table of the primary antibodies used in the present study.
Antibody Type Antigenretrieval Source Binding locus
Ubiquitin[1:1000] Mouse (mono) Citric acid Invitrogen UK, (cat: 13.1600) Ubiquitin polypeptide (50)
S830[1:20000] Sheep (poly) Citric acid Bates lab. Kings College London mHTT: N-terminal exon 1 to 53Q (32)
EM48[1:500] mouse (mono) Citric acid Millipore UK, (cat: MAB5374) mHTT: N-terminal (AA1-212) of exon-1 and 82-150Q (16)
MW8[1:1000] mouse (mono) Citric acid see “*” below mHTT: C-Terminal 8AA (AEEPLHRP) sequence of exon1 (34)
1C2[1:4000] mouse (mono) Formic acid Millipore UK, (cat: MAB1574) polyglutamine stretches of >38Q (31)
The concentration used for each antibody is stated in square brackets beneath the antibody name, and mono/polyclonal nature and antibody speciﬁes is
summarised under the “Type” heading. All antibodies except 1C2 used citric acid antigen retrieval. Where the antibodies were obtained is listed under the
“Source” heading (*MW8 was developed by Patterson and colleagues[34], was obtained from the Development Studies Hybridoma Bank, created by
NICHD of the NIH and maintained at the University of Iowa, Department of Biology, Iowa City, IA52242), and the speciﬁc binding epitope of the antibodies
is listed under the heading “Binding locus”. S830 was kindly provided by Prof Bates (Kings College London).
doi:10.1371/journal.pone.0155834.t002
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Stereology. Two dimensional stereology was performed on an Olympus BX50 microscope
(Olympus Optical Co. Tokyo, Japan) with PC-based image analysis software (Olympus C.A.S.
T. grid system v1.6.). Cell counts were performed on a 1:6 series of S830-stained sections and
1:12 series of EM48, MW8, 1C2 and ubiquitin-stained sections throughout the entire left stria-
tum of each mouse. Briefly, the striatum was outlined under a 4× objective lens and the
enclosed area was calculated by the C.A.S.T grid software. Sections within a defined volume of
the striatum were then sampled at random and cells were counted under a 100× objective lens
using a 265 μm2 2D optical dissector counting frame. The total number of affected cells in the
structure per section was calculated using the Abercrombie correction[50]:
C ¼ Sc  ðSA=SaÞ  f
C: The total number of cells; ∑c: The total number of cells counted; ∑A: The sum of all the
inclusion areas; ∑a: The sum of all the sample area; f: The frequency of sectioning.
Affected cells were identified and the total numbers estimated in terms of positive immuno-
reactive-labelling; affected cells were further categorized in terms of whether they expressed
either diffuse nuclear staining alone or exhibited frank NIIs with or without additional diffuse
nuclear staining.
Statistical analyses. Initially, within strain 2-way (Antibody x Age) analyses of variance
(ANOVA) were used to determine antibody binding differences in the detection of mHTT dif-
fuse or inclusion cellular pathology within the striatum. With significance, post-hoc analysis
was undertaken with pairwise analysis using Tukey HSD tests and for age-related analysis inde-
pendent t-tests were used where appropriate. As there were many possible interactions avail-
able for analysis, selected main effects and interaction comparisons are reported, and post-hoc
significances are simply marked by lowest significance level (in parenthesis) amongst the com-
parator groups. All statistical analyses were performed using the Genstat statistical package
(v13.2; VSN International, Hemel Hempstead, UK) with significance taken at the 0.05 level.
Results
R6/1 (Fig 1 and photomicrographs A-E Figs 2 and 3)
In the R6/1 mouse the level of diffuse staining changed differentially with age and antibody
(Fig 1A: Age x Antibody, F4,31 = 7.15, p<0.001). Staining for frank inclusions also varied by
antibody used (Fig 1B: Antibody: F4,31 = 48.49, p<0.01) with the relative sensitivity of the anti-
bodies not changing with age (Age x Antibody, F4,31 = 2.18, n.s.), presumably as the disease is
well advanced in these animals by 4m. Overall the most sensitive antibody in the R6/1 mouse
was EM48 (p<0.05) that detected inclusions in high numbers but was not sensitive for diffuse
staining. MW8 and S830 also detected good numbers of inclusions, but whereas MW8 also
failed to detect diffuse mHTT consistent with the EM48 profile, S830 detected diffuse mHTT
binding in both 4m old and 7m old animals. The 1C2 antibody demonstrated preferential bind-
ing to mHTT in the diffuse form in the 4m old animals and found relatively few frank inclu-
sions in 7m old mice despite the high numbers detected by other antibodies. Ubiquitin staining
was generally weak but stable at both ages in the R61 mice.
YAC128 (Fig 1 and photomicrographs F-J of Figs 2 and 3)
The YAC128 mice provided the most unique aggregation profile of the lines in the present
study. Striatal inclusion formations appeared late in the life of the mouse, despite the presence
of diffuse mHTT staining at an early age. The cellular development of diffuse striatal mHTT
staining in the absence of inclusions was differentially sensitive to the different antibodies
Assessment of mHTT Antibodies across HDMouse Lines
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Fig 1. mHTT antibody binding in young and old animals from 5 HDmousemodels. R6/1 mice
demonstrate some diffuse staining (A) but high levels of frank inclusions from 4 months of age (B). In this
mouse line EM48 was overall the most sensitive antibody, with 1C2 and ubiquitin the least. In young YAC128
mice that demonstrate only diffuse staining (C,D), ubiquitin and S830 were the most effective antibodies. As
the mice aged MW8 became the most sensitive antibody. In the HdhQ92 mice, EM48 was the most effective
Assessment of mHTT Antibodies across HDMouse Lines
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(Fig 1C: Antibody x Age, F4,34 = 14.02, p<0.001), as was the development of frank inclusions
(Fig 1D: Antibody x Age, F4,36 = 6.76, p<0.001).
In the 8m old YAC128 mice ubiquitin was the most effective antibody compared against all
others except S830 (p<0.05). No antibody detected frank inclusions at 8m. The ubiquitin stain-
ing remained high for the diffusely stained cells in the 18m animals and demonstrated greater
diffuse than punctate staining (p<0.01), suggesting that it was less able to detect frank inclu-
sions in the same animals despite their presence in high numbers being detected by other anti-
bodies. The 1C2 antibody demonstrated a similar propensity to detect diffuse staining over
frank inclusions in the 18m old mice (p<0.01). In contrast, the sensitivity of MW8 increased
markedly with age when mHTT became aggregated into inclusions (p<0.01). MW8, S830 and
EM48 were the most sensitive antibodies for detecting inclusions (p<0.05 against 1C2 and the
presence of ubiquitin). In the 18m old mice EM48 and MW8 failed to detect mHTT in cells
that did not contain an inclusion.
HdhQ92 (Fig 1 and photomicrographs K-O of Figs 2 and 3)
In the HdhQ92 mice the number of cells demonstrating diffuse staining in the absence of inclu-
sions fell with age (Fig 1E: Antibody x Age, F4,33 = 13.01, p<0.001) with a concomitant increase
in inclusions (Fig 1F: Antibody x Age, F4,34 = 4.01, p<0.01).
In the 8m old mice, post-hoc analysis revealed that of the antibodies used EM48 detected
most mHTT (p<0.05). At 8m of age this was in the diffuse form but interestingly whilst this
level of detection did not change with age, at 18m EM48 detected only inclusions. This general
pattern was maintained for each of the antibodies although S830 was able to detect a modest
number of inclusions at 8m. In the 18m old mice, post-hoc analysis revealed that S830 was the
most sensitive antibody overall (p<0.05) for detecting inclusions and was the only one that
was able to detect diffuse mHTT at this age. MW8, EM48, 1C2 and ubiquitin demonstrated
comparable levels of diffuse staining at 8m of age and inclusions at 18 months of age.
Original (B6 x 129/Ola) HdhQ150 (Fig 1 and photomicrographs P-T of
Figs 2 and 3)
The lack of binding with the EM48 antibody in this line and the backcross B6 HdhQ150 line
was expected and occurs due to the mismatch in human binding specificity of the antibody and
the restricted human component of the inserted construct (CAG repeats only) of these models.
There were significant differences in the extent of detection of both diffuse staining (Fig 1G:
Antibody x Age: F4,29 = 10.62, p<0.001) and inclusion detection (Fig 1H:Antibody x Age: F4,29
= 4.43, p<0.01) between the antibodies in the (B6 x129/Ola) HdhQ150 line.
All antibodies (except EM48) detected inclusions at 4m of age but only S830 and MW8 also
detected cells with diffuse mHTT in the absence inclusions at this age. In the 8m old mice all of
the antibodies were comparably sensitive at detecting inclusions. With advancing disease cells
with diffuse mHTT and no inclusions became undetectable at 18m of age for all antibodies. In
contrast all antibodies (except EM48) detected high levels of inclusions to comparable levels.
Of interest in this mouse line was that whereas the detection of inclusions by S830, MW8 and
antibody in the young animals (E) with S830 the most effective in the old (F) where the other four antibodies
demonstrated a consistent level of mHTT detection. For the HdhQ150 strains, both lines were insensitive to
EM48 and demonstrated relatively little binding of diffuse staining per se (original line G,H; B6 backcross I,J)
with the antibodies detecting inclusions at high levels even at a young age. The original HdhQ150 line
demonstrated consistent levels of detection with the four usable antibodies including 1C2, which was
ineffective in the B6 line. MW8 was the most sensitive antibody in the B6 line. Significance markers omitted
for clarity (See S1 File for raw data).
doi:10.1371/journal.pone.0155834.g001
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Fig 2. High power light microscopy images of mHTT antibody staining of striatal aggregation pathology
in early disease HDmice. The R6/1 mice demonstrated NIIs with all antibodies (A,F,K,P,U), whereas the
YAC128 mice demonstrate no NIIs but faint diffuse staining with all antibodies (G,L,Q,V) except S830 (B). The
antibodies also failed to detect NIIs in the HdhQ92 line at this age (Photomicrographs C,H,M,R,W) but did
demonstrate diffuse staining with all. Both HdhQ150 lines were insensitive to EM48 (N,O) with the original
Assessment of mHTT Antibodies across HDMouse Lines
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1C2 increased significantly with age (p<0.05), but the ubiquitin antibody maintained a con-
stant level of staining across the age groups.
B6 HdhQ150 (Fig 1 and photomicrographs U-Y of Figs 2 and 3)
As with all of the other mouse lines the detection of diffuse mHTT by the different antibodies
across the two age groups differed significantly (Fig 1I: Antibody x Age, F4,30 = 12.47,
p<0.001). This was also the case for the detection of frank inclusions (Antibody x Age, F4,31 =
4.44, p<0.01).
At 8m of age MW8 was able to detect high levels of inclusions with post-hoc analysis deter-
mining that it was the most sensitive of the antibodies at this age (p<0.01). There were relative
few cells that contained diffuse mHTT staining at either age. Despite the sensitivity of MW8,
1C2 failed to detect either diffuse staining or inclusions in 8m old animals and identified few
inclusions in 18m old animals. Aside fromMW8, only ubiquitin demonstrated high levels of
staining in 8m old B6 HdhQ150 mice. As with the other mouse lines the levels of ubiquitin
staining were constant over the 8m to 18m period. In the older 18m mice, post hoc analysis
determined that MW8 remained the most sensitive of the antibodies for detecting frank inclu-
sions demonstrating comparable levels across the two age groups (p<0.05), but interestingly
S830 also detected much high levels of inclusions in the old mice (p<0.01) than it did at 8m
despite the large numbers detected by MW8 in the younger mice, suggesting a change in con-
formation of the mHTT protein was required for the S830 binding at 18m of age.
The means and standard errors of the data sets are contained in Table 3 below. The table
depicts how each antibody performs for each mouse line at the ages used and shows were anti-
bodies failed in particular mouse lines.
Discussion
The results from the present study demonstrate clear differences in antibody effectiveness
within the HD mouse lines. In the R61 mice S830, MW8 and EM48 were the most effective is
detecting inclusion formations, with S830 and 1C2 also identifying cells with diffuse staining in
the absence of an inclusion. In the YAC12 mice, diffuse staining of ubiquitin and MW8 were
the most effective in 8m old mice. In the 18m old mice, MW8 was most sensitive in labelling
mature inclusions but ubiquitin still had affinity for the diffuse staining. For the HdhQ92
model, there was a clear separation between early diffuse staining and late inclusion staining.
EM48 was the most sensitive in the young animals with S830 detecting most inclusions at 18
months of age. In the original HdhQ150 mice, S830 was the most effective antibody overall,
but MW8, 1C2 and ubiquitin were also effective at detecting frank inclusions. In the B6
HdhQ150 variant, MW8 was the most effective. As expected, the different mouse lines demon-
strated different levels of sensitivity towards the different antibodies used. As a general rule,
(and under the conditions employed in the present study) S830 and MW8 were the most effec-
tive of the antibodies, and1C2 the least (excepting the lack of EM48 binding in the HdhQ150
lines).
When the performance of each of the antibodies is considered in more general terms across
the mouse lines it was clear that antibody selectivity for either form of mHTT was mouse line
specific and was not generalizable across the strains, with the exception of S830 that demon-
strated good levels of detection of mHTT in both diffuse and frank inclusion form, in all mouse
HdhQ150 line also being insensitive to 1C2 (X), but the Photomicrographs for S830 (D), MW8 (I) and ubiquitin
(X) in the original line demonstrated good sensitivity for NIIs, as they did for the B6 variant (Photomicrographs E,
J, Y respectively). Scale bar = 10 μm.
doi:10.1371/journal.pone.0155834.g002
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Fig 3. High power light microscopy images of mHTT antibody staining of striatal aggregation pathology in later disease
HDmice. The R6/1, YAC128 and HdhQ92 mice were sensitive to each of the antibodies (R6/1 Photomicrographs A,F,K,P,U;
YAC128 Photomicrographs B,G,L,Q,V; HdhQ92 Photomicrographs C,H,M,R,W), whereas both HdhQ150 lines where sensitive to
all but EM48 (B6 HdhQ150 Photomicrographs E,J,O,T,Y; original HdhQ150 Photomicrographs D,I,N,S,X). Scale bar = 10 μm.
doi:10.1371/journal.pone.0155834.g003
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lines relative to the other antibodies used. In contrast MW8 demonstrated most variability:
exclusively selective for mature inclusions in the R6/1 and B6 HdhQ150 mice; comparable lev-
els of detection for diffuse mHTT and inclusions at 8m but exclusive binding to mature inclu-
sions at 18m in the original HdhQ150s; comparable detection of early diffuse staining and late
inclusion staining in the HdhQ92s; and in the YAC128 mouse a modest level of detection of
diffuse mHTT in 8m old mice that developed to be the most sensitive antibody in the 18m old
mice. 1C2 binding was generally one of the weakest antibodies throughout suggesting that anti-
bodies that target only the polyglutamine stretch of the mHTT may not be optimal. This was
highlighted previously with MW family of antibodies in the R6/2 mouse [32], which were spe-
cific to particular cellular compartments. MW7 binding to the polyglutamine epitope was weak
in HD mice that had clearly demonstrated NIIs with the polyP sensitive MW8 [32], suggesting
that in some mouse lines antibodies directed at the polyglutamine stretch of the mHTT protein
may not be the most sensitive for mHTT detection. In the present study, S830 and EM48 both
of which were highly sensitive and bind to the polyglutamine stretch of the mHTT, also bind to
a section of exon1 which likely aids mHTT detection. Of significant interest was that ubiquitin
staining was remarkably stable across the age groups within each mouse line.
Table 3. Means and standard errors of the data sets used in the present study. (See S1 File for raw data).
Mean Number of Cells with Diffuse mHTT (no NIIs) Mean Number of Cells with mHTT NII
Young Old Young Old
Antibody Mean Std Error Mean Std Error Mean Std Error Mean Std Error
R6/1 S830 200750 39542 135071 45743 572564 112639 438681 49180
MW8 0 - 0 - 524286 63345 530353 23636
EM48 0 - 0 - 600399 45241 747742 47947
1C2 204951 35059 0 - 0 - 99545 13300
Ubiquitin 53715 8922 67425 16979 194368 33385 187625 15816
YAC128 S830 417324 39117 165299 35665 0 - 281218 41722
MW8 169262 46895 0 - 17361 2053 528099 167620
EM48 188560 33442 0 - 0 - 382846 37697
1C2 156588 25003 268451 52096 0 - 97166 21196
Ubiquitin 463573 38514 339775 75899 0 - 132443 15811
HdhQ92 S830 325042 27424 78398 13231 145545 20202 639032 68298
MW8 277823 48395 0 - 0 - 370060 62949
EM48 487886 14714 0 - 0 - 411493 43713
1C2 153323 50856 0 - 0 - 299920 53162
Ubiquitin 204037 49615 0 - 0 - 235407 40015
HdhQ150 S830 193762 29829 0 - 269899 46802 581021 43156
(B6x129/Ola) MW8 198015 66316 0 - 201010 47904 569580 114339
EM48 0 - 0 - 0 - 0 -
1C2 0 - 0 - 316529 81570 494420 33892
Ubiquitin 0 - 0 - 402699 65845 442095 44852
HdhQ150 S830 92378 29078 0 - 122834 40027 448266 22479
(B6) MW8 0 - 0 - 729092 204290 638207 52992
EM48 0 - 0 - 0 - 0 -
1C2 0 - 0 - 0 - 190867 18399
Ubiquitin 54969 15067 0 - 405961 80919 387533 80804
doi:10.1371/journal.pone.0155834.t003
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There has been a long-standing question regarding the role of ubiquitin and related prote-
olysis in the pathogenesis of HD [38–40] (reviewed in [51]). The evidence remains inconclu-
sive as to whether the ubiquitination of mHTT is an early stage event, a late stage event or
occurs concomitantly with aggregation development [26, 41, 42]. For the present study, it
was not possible to explore the nature of ubiquitin staining in greater detail, but from our
data we can see that in the R6/1 mice ubiquitin staining was relatively low at both ages sug-
gesting that many inclusions available did not contain ubiquitin. In contrast ubiquitin bind-
ing in the YAC128 mice was particularly high in 8m old animals relative to the other
antibodies used and this was in the absence of frank inclusion formations suggesting that in
this mouse line, ubiquitin binding was an early event in the development of inclusion forma-
tions. However, in the HdhQ92 mouse diffuse and more punctate staining were to compara-
ble levels with ubiquitin, again suggesting that ubiquitin is present in both diffuse mHTT and
later inclusions. In both HdhQ150 lines concentrated ubiquitin staining was found at both
ages as comparable levels. The variation across the mouse lines in ubiquitin binding suggests
that generalisations between models are not informative. Taking our data as a whole is clear
that ubiquitin binding of mHTT can be present during the early stages of inclusion develop-
ment and not simply a late stage event as previously suggested [26, 52]. In agreement with
these studies, our data suggests that not all inclusions are ubiquitinated [26, 52]. Further
hypothesising about the role of ubiquitin in the development of inclusion bodies is beyond
the scope of the present report.
Simply using different background strains produced marked effects on the binding profiles
of the antibodies. Whilst overall levels of pathology were similar in the 18m old HdhQ150 mice
of the two lines with S830 and MW8 demonstrating good binding, levels of 1C2 binding was
particularly poor in the pure B6 line again demonstrating that even in mouse lines that carry
the same construct but on different backgrounds, antibody sensitivity may vary. In the present
study, this variation in 1C2 binding occurred even when the two mouse lines demonstrated
comparable asymptotic sensitivity with other antibodies.
Conclusions
The data from the present study highlights the variation in antibody binding that exists
within the HD mouse lines and suggests that generalisations between studies using different
antibodies within the same line should be made with caution. Similarly, generalisation across
mouse lines with the same antibody may not be advisable. With reference to the role of ubi-
quitin in the development of inclusion bodies, the present study demonstrates the ubiquitin
binding was remarkably consistent across age groups regardless of HD mouse model or
mHTT aggregation stage even when binding of the other antibodies increased with age. Our
data suggest that ubiquitin binding is not present in all inclusion bodies or necessary for their
development.
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